You’re cruising through a transplant question in your Q-bank, you pick “acute rejection,” and you move on… until you miss the next one because the stem looked similar but the timing and pathology were totally different. This is one of those topics where every distractor is a testable diagnosis, and the only way to get consistent is to train your brain to map time course + mechanism + histology + treatment automatically.
Tag: Immunology > Transplant & Autoimmune
The Clinical Vignette (Q-bank style)
A 52-year-old man with end-stage renal disease undergoes a deceased-donor kidney transplant. Crossmatch testing was reportedly “negative.” Within minutes to hours after reperfusion, the graft becomes mottled and cyanotic, with no urine output. Doppler ultrasound shows little to no blood flow to the transplant kidney. The graft is removed. Pathology shows widespread thrombosis and fibrinoid necrosis of vessel walls.
What is the most likely mechanism?
Correct Answer: Hyperacute rejection due to preformed anti-donor antibodies
Why it’s correct:
- Timing: Minutes to hours after transplant is the biggest giveaway.
- Mechanism: Pre-existing antibodies in the recipient bind donor antigens (most often anti-ABO or anti-HLA).
- Pathology: Antibody binding triggers complement activation, endothelial injury, and a thrombotic occlusion picture.
- Gross/clinical: Mottled graft, immediate failure, absent perfusion.
High-yield mechanism summary
- Type II hypersensitivity (antibody-mediated cytotoxicity)
- Classic setting: prior sensitization via
- Pregnancy
- Blood transfusions
- Previous transplant
Key histology clues
- Fibrinoid necrosis of vessel walls
- Thrombi within graft vasculature
- Neutrophils may be seen with acute inflammation, but thrombosis is the headline
Management
- Usually not salvageable → remove graft
- Prevention is everything:
- ABO compatibility
- Negative crossmatch (recipient serum vs donor lymphocytes)
- Panel reactive antibody (PRA) screening (conceptually)
Why Every Answer Choice Matters (Systematic Distractor Breakdown)
Here’s how Step questions try to bait you—and how to shut it down.
Distractor 1: Acute cellular rejection (T-cell mediated)
When it happens: Weeks to months (can occur earlier if immunosuppression is inadequate; can also occur later)
Mechanism: Recipient T cells recognize donor MHC → attack graft parenchyma and vessels
- Type IV hypersensitivity
Presentation:
- Rising creatinine, tenderness over graft (sometimes)
- Less “instant catastrophic thrombosis,” more “subacute organ dysfunction”
Histology:
- Interstitial lymphocytic infiltrate
- Tubulitis (lymphocytes invading tubules)
- Can include endarteritis (“intimal arteritis”)—lymphocytes in vessel intima
Treatment:
- High-dose steroids
- If refractory: anti–T-cell therapies (e.g., antithymocyte globulin). Some curricula also mention calcineurin inhibitor optimization.
How they trick you:
They’ll mention “early after transplant,” but if it’s minutes-hours, that’s not acute cellular rejection. Think days-weeks at earliest, not on the OR table.
Distractor 2: Acute antibody-mediated rejection (ABMR)
When it happens: Days to weeks (can be later too)
Mechanism: Newly formed anti-donor antibodies (not preformed) → endothelial injury
- Often against donor HLA
Presentation:
- Graft dysfunction developing over days/weeks (not immediate)
- May have fever, graft tenderness
Histology / Tests:
- C4d deposition in peritubular capillaries (a classic board clue for complement activation)
- Microvascular inflammation, edema, hemorrhage
Treatment:
- Plasmapheresis + IVIG
- Sometimes adjuncts like anti-CD20 (center-dependent), but the Step-level core is plasmapheresis/IVIG ± steroids.
How they trick you:
If the stem says “antibodies” you might jump to hyperacute—but timing separates them:
- Hyperacute = preformed antibodies, minutes-hours, thrombosis
- Acute ABMR = new antibodies, days-weeks, C4d positivity
Distractor 3: Chronic rejection
When it happens: Months to years after transplant (slow decline)
Mechanism: Mixed immune mechanisms (both T-cell and antibody-driven injury) → progressive vascular narrowing and fibrosis
Presentation:
- Gradual graft dysfunction: chronic rise in creatinine, hypertension
- Often irreversible decline
Histology:
- Intimal thickening and luminal narrowing (chronic vasculopathy)
- Interstitial fibrosis
- Parenchymal atrophy
- In kidney: glomerulopathy and tubular atrophy are classic concepts
Treatment:
- Limited response to immunosuppression
- Often eventual retransplant
How they trick you:
They’ll use vague phrases like “transplant a year ago, slowly worsening function.” That should immediately call chronic rejection, not “recurrent disease” or “drug toxicity” unless other details support it.
Distractor 4: Graft-versus-host disease (GVHD)
When it happens: Classically days to weeks after transplant of immunocompetent donor T cells into an immunocompromised host
Where it happens: Most associated with bone marrow (hematopoietic stem cell) transplant, not solid organs
Mechanism: Donor T cells attack recipient tissues
Presentation (boards love this triad):
- Rash
- Jaundice
- Diarrhea
How they trick you:
They’ll mention “transplant” and “immune reaction,” but if it’s a kidney transplant failing immediately, GVHD is not the move. Think GVHD when the question is about skin/GI/liver after bone marrow transplant.
Distractor 5: Post-transplant lymphoproliferative disorder (PTLD)
When it happens: Often months after transplant (variable)
Mechanism: EBV-driven B-cell proliferation due to immunosuppression
Presentation:
- Fever, weight loss, lymphadenopathy, organ masses
- Can involve the transplanted organ but doesn’t present as immediate graft thrombosis
How they trick you:
Any time you see “transplant + immunosuppression,” they want you to think infection/malignancy. But PTLD is not an immediate post-reperfusion catastrophe.
The Money Table: Hyperacute vs Acute vs Chronic
| Feature | Hyperacute | Acute (cellular / antibody-mediated) | Chronic |
|---|---|---|---|
| Timing | Minutes–hours | Days–months (often weeks) | Months–years |
| Main driver | Preformed IgG vs ABO/HLA | T cells (cellular) and/or new antibodies (ABMR) | Progressive immune-mediated injury |
| Core pathology | Thrombosis, fibrinoid necrosis | Cellular: tubulitis, lymphocytes; ABMR: C4d+ | Intimal thickening, fibrosis, atrophy |
| Clinical clue | Immediate graft failure, mottled graft | Rising creatinine, tenderness, dysfunction | Slow decline in function |
| Treatment | Prevent; usually remove graft | Steroids (cellular); plasmapheresis + IVIG (ABMR) | Limited; retransplant often |
High-Yield USMLE Hooks & Pitfalls
1) Time course is not a suggestion—it’s the diagnosis
- Minutes-hours → hyperacute
- Weeks-months → acute
- Months-years → chronic
2) Don’t ignore the vascular clues
- Thrombosis + fibrinoid necrosis → antibody catastrophe (hyperacute)
- Intimal thickening → chronic vasculopathy
3) Know what “C4d positive” is pointing to
- C4d deposition = complement activation from antibody-mediated rejection (classically acute ABMR)
4) Crossmatch “negative” in the stem can be a trap
Real-world nuance aside, test writers may still give “negative crossmatch” but include a scenario consistent with hyperacute rejection to force you to recognize the classic pathology and timing. When the vignette screams hyperacute (immediate thrombosis), pick it.
Rapid-Fire Self-Check (what to say in your head)
- “Immediate failure + thrombosis” → hyperacute, preformed antibodies
- “Weeks after + tubulitis/endarteritis” → acute cellular, T cells, steroids
- “Days-weeks + C4d” → acute ABMR, plasmapheresis/IVIG
- “Year later + progressive narrowing/fibrosis” → chronic rejection
- “Bone marrow transplant + rash/diarrhea/jaundice” → GVHD